CLAIMS

1. Use of a CD96-inhibitory agent in the manufacture of a medicament for~~A method of~~ reducing or relieving immune inhibition in a mammal, said ~~method~~ use including the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal includes the CD96-inhibitory agent to be administered to the mammal.

2. The ~~method~~ use of Claim 1, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal does not include, or depend upon, killing of CD96-expressing cells in the mammal.

~~3. The method of Claim 1 or Claim 2, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal includes administering a CD96-inhibitory agent to the mammal.~~

~~4.~~3. The use ~~method~~ of Claim ~~3~~1, wherein the CD96-inhibitory agent at least partly blocks or inhibits CD96 binding to CD155 and/or intracellular signaling by CD96.

~~5.~~4. The use ~~method~~ of Claim 43, wherein the CD96-inhibitory agent is an anti-CD96 antibody or antibody fragment.

~~6.~~5. The use ~~method~~ of any preceding claim which includes ~~administering~~ one or more other therapeutic agents to be administered.

~~7.~~6. The use ~~method~~ of Claim ~~6~~5, wherein the one or more other therapeutic agents include a chemotherapeutic agent and one or more antibodies or antibody fragments that bind PD1 and/or CTLA4.

~~8.~~7. The use ~~method~~ of any preceding claim, which increases or enhances cytokine and/or chemokine expression and/or secretion by one or more cells in the mammal.

~~9.~~8. The use ~~method~~ of Claim ~~8~~7, wherein the cytokine and/or chemokines include MIP-1α, MIP-lβ, RANTES, TNF-a and IFN-γ.

~~10.~~9. The use ~~method~~ of Claim ~~9~~8, wherein the cytokine is interferon γ (IFN-γ).

~~11.~~10. The use ~~method~~ of Claim ~~8~~7, Claim ~~9~~8 or Claim ~~10~~9, wherein the one or more cells are T cells, inclusive of $CD4^+$ and $CD8^+$ T cells, γδT cells and NK T cells and natural killer (NK) cells.

~~12.~~11. The use ~~method~~ of any preceding claim, which treats or prevents cancer or cancer metastasis in the mammal.

~~13.~~12. The use ~~method~~ of any preceding claim, which treats or prevents a viral infection in the mammal.

~~14.~~13. The use ~~method~~ of any preceding claim, wherein the mammal is a human.

~~15.~~14. A method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent, said method including the step of determining whether a candidate molecule is capable of at least partly inhibiting or reducing CD96 activity to thereby relieve immune inhibition and/or enhance or restore immune surveillance in a mammal.

~~16.~~15. The method of Claim ~~15~~14, wherein the CD96-inhibitory agent is an antibody or antibody fragment.

~~17.~~16. The method of Claim ~~15~~ 14 or Claim ~~16~~15, wherein the CD96-inhibitory agent is an anti-cancer agent.

~~18.~~17. The method of Claim ~~15~~14, Claim ~~16~~ 15 or Claim ~~17~~16, wherein the CD96-inhibitory agent is an anti-viral agent.

~~19.~~18. The method of any one of Claims ~~15~~14-~~18~~17, wherein the mammal is a human.

~~20.~~19. A CD96-inhibitory agent screened, designed, engineered or otherwise produced according to the method of any one of Claims ~~15~~14-~~19~~18.

~~21.~~20. The CD96-inhibitory agent of Claim ~~20~~ 19 for use according to ~~the method of~~ any one of Claims 1-~~14~~13.